Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Public ClinicalTrials.gov record NCT03249792. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Study identification
- NCT ID
- NCT03249792
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Interventions
- MK-2118 (IT) Drug
- MK-2118 (SC) Drug
- Pembrolizumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2017
- Primary completion
- Feb 21, 2023
- Completion
- Feb 21, 2023
- Last update posted
- Jul 23, 2025
2017 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Moores Cancer Center ( Site 0004) | La Jolla | California | 92093 | — |
| UCLA ( Site 0003) | Los Angeles | California | 90095 | — |
| University of Chicago ( Site 0002) | Chicago | Illinois | 60637 | — |
| New York Presbyterian Hospital/Columbia University ( Site 0001) | New York | New York | 10032 | — |
| UPMC Hillman Cancer Centers ( Site 0007) | Pittsburgh | Pennsylvania | 15232 | — |
| Mary Crowley Cancer Research Center ( Site 0005) | Dallas | Texas | 75230 | — |
| MD Anderson Cancer Centr. ( Site 0006) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03249792, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2025 · Synced May 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03249792 live on ClinicalTrials.gov.